ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
OncoCyte Corporation

OncoCyte Corporation (OCX)

3,72
0,00
(0,00%)
Fermé 27 Septembre 10:00PM
3,72
0,00
( 0,00% )
Avant marché: 2:00AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
3,72
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
3,72
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
8 261 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,85
Bénéfice par action (BPA)
-3,48
Chiffre d'affairess
7,27M
Bénéfice net
-28,72M

À propos de OncoCyte Corporation

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers.... OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests. Show more

Secteur
In Vitro,in Vivo Diagnostics
Industrie
In Vitro,in Vivo Diagnostics
Site Web
Siège social
Irvine, California, USA
Fondé
-

OCX Dernières nouvelles

EchelonDx & Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offeri...

Echelon Diagnostics, Inc., a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE American: OCX), a...

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update...

OncoCyte Reports Second Quarter 2018 Financial Results and Positive Corporate Developments

-Encouraging Study Data Drives Continued Development of DetermaVu™ Lung Cancer Diagnostic Test- -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE...

Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte

ALAMEDA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today...

OncoCyte to Report Second Quarter 2018 Financial Results on August 14, 2018

ALAMEDA, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced...

OncoCyte Announces At-Market $3.59 Million Offering of Common Stock and Warrants

ALAMEDA, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer...

OncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test

- Results suggest improved performance of next-generation test- Study results support move to new diagnostic testing platform- Significant development work required to fully validate this recent...

OncoCyte Reports First Quarter 2018 Financial Results

ALAMEDA, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial...

OncoCyte to Report First Quarter 2018 Financial Results on May 15, 2018

ALAMEDA, Calif, May 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced...

Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of Directors

ALAMEDA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced the appointment of Ronald Andrews, Jr., an executive with over 30 years’...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
GGNGAMCO Global Gold Natural Resources and Income Trust
US$ 4,88
(13,36%)
5
CNXTVanEck ChiNext ETF
US$ 25,80
(8,95%)
1 000
EONREON Resources Inc
US$ 1,05
(8,25%)
6,67k
ASHSXtrackers Harvest CSI 500 China AShares Small Cap ETF
US$ 29,00
(8,23%)
259
CHAUDirexion Daily CSI 300 China A Share Bull 2X Shares
US$ 17,24
(8,02%)
81,21k
AMBIAmbipar Emergency Response
US$ 2,03
(-55,97%)
2
TOVXTheriva Biologics Inc
US$ 1,67
(-18,14%)
190k
SOARVolato Group Inc
US$ 0,4367
(-14,87%)
167,46k
ATCHAtlasClear Holdings Inc
US$ 0,2573
(-12,18%)
128,38k
GRFXGraphex Group Limited
US$ 0,173
(-12,09%)
105
YANGDirexion Daily FTSE China Bear 3X Shares New
US$ 4,09
(-0,73%)
3,92M
FXIiShares China Large Cap
US$ 31,93
(0,03%)
3,14M
YINNDirexion Daily FTSE China Bull 3X Shares
US$ 37,46
(0,29%)
2,75M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 39,30
(-0,88%)
2,12M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 18,95
(0,80%)
1,75M
Aucune Discussion Trouvée
Ajouter une Discussion